Sildenafil

Sildenafil Struktur
139755-83-2
CAS-Nr.
139755-83-2
Englisch Name:
Sildenafil
Synonyma:
Revatio;Sildenafil Powder;5-[2-ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazol[4,3d]pyrimidin-7-one;viagTa;Viagar;UK-92480;Sildefil;SIDANAFIL;SILDENAFIL;SiIdenafiI
CBNumber:
CB2747316
Summenformel:
C22H30N6O4S
Molgewicht:
474.58
MOL-Datei:
139755-83-2.mol

Sildenafil Eigenschaften

Schmelzpunkt:
187-189°C
Dichte
1.39±0.1 g/cm3(Predicted)
Flammpunkt:
9℃
storage temp. 
Sealed in dry,Store in freezer, under -20°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
pKa 8.7 (Uncertain)
Farbe
White to Off-White
InChIKey
BNRNXUUZRGQAQC-UHFFFAOYSA-N
CAS Datenbank
139755-83-2(CAS DataBase Reference)
EPA chemische Informationen
7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl- (139755-83-2)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xi,T,F
R-Sätze: 36/37/38-39/23/24/25-23/24/25-11
S-Sätze: 22-24/25-36-26-45-36/37-16-7
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  1
HS Code  38220090
Giftige Stoffe Daten 139755-83-2(Hazardous Substances Data)
Bildanzeige (GHS) GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H225 Flüssigkeit und Dampf leicht entzündbar. Entzündbare Flüssigkeiten Kategorie 2 Achtung GHS hazard pictogramssrc="/GHS02.jpg" width="20" height="20" /> P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 Schädigt die Organe. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" /> P260, P264, P270, P307+P311, P321,P405, P501
Sicherheit
P210 Von Hitze, heißen Oberflächen, Funken, offenen Flammen und anderen Zündquellenarten fernhalten. Nicht rauchen.
P260 Dampf/Aerosol/Nebel nicht einatmen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P301+P310 BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P311 GIFTINFORMATIONSZENTRUM/Arzt anrufen.

Sildenafil Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.

S-Sätze Betriebsanweisung:

S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.

Beschreibung

Sildenafil was launched as Viagra in the US for the treatment of organic orland psychological male erectile dysfunction (ED). It is an orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection.

Chemische Eigenschaften

Sildenafil citrate is a white to off-white crystalline powder soluble in DMF, acetic acid and slightly soluble in methanol. Solubility of sildenafil citrate is pH dependent and it decreases with increase of pH. pH ranges between 3.7 and 3.8 and the pKa from 8.2 to 9.6.

Verwenden

Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor. It is indicated for the treatment of erectile dysfunction (ED). Sildenafil is an orally active selective type 5 cGMP phosphodiesterase inhibitor.

synthetische

The first synthetic route of sildenafil accomplished the preparation of its pyrazole derivative from ethyl 3-butyrylpyruvate and hydrazine hydrate in acetic acid, followed by the selective N-methylation of the pyrazole ring with dimethyl sulfate. The carboxylic acid was obtained after alkaline hydrolysis was subjected to nitration, followed by treatment with concentrated ammonium hydroxide solution to sequentially deliver the corresponding carboxamide derivative. The nitro group of the mentioned carboxamide derivative was then reduced to an amino group by stannous chloride/hydrochloric acid in ethanol, leading to the formation of the main 4-aminopyrazole structure. Mild amidation of the aminopyrazole derivative by the appropriate benzoyl chloride was performed, followed by cyclization mediated by hydrogen peroxide under basic environment which led to the formation of pyrimidinone heterocycle ring. Chloro-suIphonylation of pyrimidinone derivative imposed selectively on the 50 position of the phenyl ring, led to the aroyl sulfonyl chloride derivative which was then coupled with N-methylpiperazine to afford sildenafil.
synthesis of sildenafil
synthesis of sildenafil

Definition

ChEBI: Sildenafil is a pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. It has a role as a vasodilator agent and an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor. It is a pyrazolopyrimidine, a member of piperazines and a sulfonamide.

Indications

Sildenafil (Viagra) is a selective inhibitor of PD-5, an enzyme that inactivates cGMP. Vardenifil (Levitra) is a particularly effective inhibitor of PD-5. It has a shorter onset of action and can be used in smaller doses than sildenafil. Other drugs used in the treatment of ED exert their effects through other biochemical pathways, both central and peripheral.

Mechanism of action

Sildenafil is readily absorbed after oral administration and reaches peak plasma levels after about an hour. It undergoes hepatic metabolism and has a terminal half-life of about 4 hours.An initial dose of 50 mg is taken about an hour prior to sexual activity to induce penile erection.

Clinical Use

Sildenafil is a selective inhibitor of cGMP-specific PD-5 and therefore inhibits the degradation of cGMP. PD-5, the predominant type in the corpus cavernosum, also is present in other tissues (e.g., lungs, platelets, and eye). The selective inhibition of this enzyme facilitates the release of nitric oxide and smooth muscle relaxation of the corpus cavernosa. Sildenafil enhances erection by augmenting nitric oxide–mediated relaxation pathways. It has been suggested that sildenafil’s mechanism of action is due to cross-talk between cGMP- and cAMPdependent transduction pathways within the cavernous muscles.

Nebenwirkungen

Orally administered sildenafil is an effective and well-tolerated treatment for men with ED, including those with diabetes mellitus. It has also been used for so-called salvage therapy in men who do not respond to intracorporeal injections of other agents. Headache is a common side effect, as are flushing and rhinitis.More serious side effects include definite or suspected myocardial infarctions and cardiac arrest.

Enzyminhibitor

Sildenafil is rapidly absorbed and peaks in concentration (127–560 ng/mL) after 0.5 to 2.0 hours, displaying a half-life of 3 to 4 hours for the full therapeutic dose (25–100 mg). It is 96% bound to plasma proteins and is metabolized by the liver CYP3A4. The metabolite N-desmethylsildenafil possesses approximately 50% of the activity of the parent molecule.

Stoffwechsel

In vitro metabolism studies for sildenafil have shown that the primary metabolite, N-desmethylsildenafil, and the minor metabolite, oxidative opening of the piperazine ring, are mediated by CYP3A4, CYP2C9, CYP2C19, and CYP2D6. The estimated relative contributions to clearance were 79% for CYP3A4, 20% for CYP2C9, and less than 2% for CYP2C19 and CYP2D6. These results demonstrate that CYP3A4 is the primary cytochrome mediating N-demethylation and that drugs inhibiting CYP3A4 likely impair sildenafil biotransformation and clearance. The pharmacokinetics of radiolabeled sildenafil were consistent with rapid absorption, first-pass metabolism, and primarily fecal elimination of N-demethylated metabolites. The absorption of sildenafil following oral administration was rapid (~92%), whereas the oral bioavailability was approximately 38% as a result of first-pass metabolism.

Sildenafil Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

139755-83-2()Verwandte Suche:


  • SILDENAFIL
  • 7H-Pyrazolo[4,3-d]pyriMidin-7-one, 5-[2-ethoxy-5-[(4-Methyl -1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-
  • Sildenafil solution
  • 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d] pyrimidin-7-one
  • 5-[2-Ethoxy-5-[(4-methyl-piperazin-1-yl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
  • 5-[2-ethoxy-5-(4-Methylpiperazine-1-sulfonyl)phenyl]-1-Methyl-3-propyl-1H,6H,7H-pyrazolo[4,3-d]pyriMidin-7-one
  • 1-[[3-(4,7-Dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-Methylpiperazine
  • 5-[2-Ethoxy-5-[(4-Methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-7H-pyrazolo[4,3-d]pyriMidin-7-one
  • UK-92480
  • sildenafil BPC
  • 5-(2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YL-SU LFONYL)PHENYL)-1-METHYL-3-N-PROPYL-6-DIH YDRO-7H-PYRAZOL(4,3-D)PYRIMIDIN-7-ONE
  • Sildefil
  • 5-(2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL)-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE CITRATE
  • 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsul-fonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • viagTa
  • SIDANAFIL
  • 5-[2-Ethoxy-5-(4-methylpiperazin-1-yl-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazol[4.3-d]pyrimidin-7-one
  • 4-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-9-methyl-7-propyl-3,5,8,9-tetrazabicyclo[4.3.0]nona-3,7,10-trien-2-one
  • Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-
  • Methanol (test Sildenafil, 1.0 mg/mL)
  • Sildenafil citrate salt
  • sildenafil Whatsapp
  • SILDENAFIL CITRATE CAS NO.171599-83-0
  • Sildenafile
  • Manufacturers wholesale 139755-83-2 sildenafil citrate powder CAS NO.139755-83-2
  • Sildenafil CAS: 139755-83-2
  • Sildenafil h
  • 5-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • SiIdenafiI
  • 99% high purity Sildenafil CAS No 139755-83-2
  • Sildena (Viagr)
  • Hot sale Sildenafil
  • sildenafll
  • Sildenafil USP/EP/BP
  • Sildenifil?citrate
  • China Factroy Supply 99% Pure Sildenafil Powder
  • Sildenafil Cirtrate
  • Sildenafil Tadanafil
  • 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one
  • SildenafilQ: What is Sildenafil Q: What is the CAS Number of Sildenafil Q: What is the storage condition of Sildenafil Q: What are the applications of Sildenafil
  • 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazol[4,3d]pyrimidin-7-one
  • Revatio
  • Sildenafil Powder
  • 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1H,6H,7H-pyrazolo[4,3-d]pyrimidin-7-one
  • Viagar
  • High Purity 99% Sildenafil
  • Apoptosis,Autophagy,inhibit,Inhibitor,Sildenafil,UK92480,Phosphodiesterase (PDE),UK 92480
  • 5-(2-ethoxy-5-((1-methylpiperidin-4-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
  • Sildenafil Impurity 83
  • Selamectin Impurity 10
  • 139755-83-2
  • 171599-83-1
  • 39755-83-2
  • C22H3N6O4SC6H8O7
  • C22H30N6O4S
  • TAMIFLU
  • pharmaceutical intermediates
Copyright 2019 © ChemicalBook. All rights reserved